To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI)
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) br...
Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response t...
ABSTRACTObjective: To determine the predictive value of Ki67 on pathological complete response (pCR)...
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive...
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) fo...
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estroge...
In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary end...
Background: The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate m...
Purpose The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferati...
Neoadjuvant hormonal therapy (NEO-HT) is a possible treatment option for breast cancer (BC) patient ...
The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine ...
Background: Neoadjuvant aromatase inhibitor therapy has been reported to improve surgical outcomes f...
PURPOSE: Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oest...
PurposeThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survi...
PURPOSE The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of surv...
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) br...
Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response t...
ABSTRACTObjective: To determine the predictive value of Ki67 on pathological complete response (pCR)...
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive...
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) fo...
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estroge...
In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary end...
Background: The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate m...
Purpose The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferati...
Neoadjuvant hormonal therapy (NEO-HT) is a possible treatment option for breast cancer (BC) patient ...
The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine ...
Background: Neoadjuvant aromatase inhibitor therapy has been reported to improve surgical outcomes f...
PURPOSE: Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oest...
PurposeThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survi...
PURPOSE The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of surv...
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) br...
Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response t...
ABSTRACTObjective: To determine the predictive value of Ki67 on pathological complete response (pCR)...